Published in final edited form as:

Mamm Genome. 2010 December ; 21(0): . doi:10.1007/s00335-010-9298-y.

Feasibility of Using Gene Expression Analysis to Study Canine Soft Tissue Sarcomas

Jennifer A. Mahoney, DVM¹, Julie C. Fisher, BS¹, Stacey A. Snyder, BS¹, and Marlene L. Hauck, DVM, PhD¹

¹Department of Clinical Sciences, North Carolina State University College of Veterinary Medicine, 4700 Hillsborough Street, Raleigh, NC 27606, USA

Abstract

The prognosis given for canine soft tissue sarcomas (STSs) is based primarily on histopathologic grade. The decision to administer adjuvant chemotherapy is difficult, since less than half of patients with high-grade STSs develop metastatic disease. We hypothesize that there is a gene signature which will improve our ability to predict development of metastatic disease in STS patients. The objective of this study was to determine the feasibility of using cDNA microarray and quantitative real-time PCR (qRT-PCR) analysis to determine gene expression patterns in metastatic versus non-metastatic canine STSs, given the inherent heterogeneity of this group of tumors. Five STSs from dogs with metastatic disease were evaluated in comparison to eight STSs from dogs without metastasis. Tumor RNA was extracted, processed and labeled for application to the Affymetrix Canine Genechip 2.0 Array. Array fluorescence was normalized using D-Chip software and data analysis was performed with JMP/Genomics. Differential gene expression was validated using qRT-PCR. Over 200 genes were differentially expressed at a false discovery rate of 5%. Differential gene expression was validated for five genes upregulated in metastatic tumors. Quantitative RT-PCR confirmed increased relative expression of all five genes of interest in the metastatic STSs. Our results demonstrate that microarray and qRT-PCR are feasible methods for comparing gene signatures in canine STSs. Further evaluation of differences in gene expression between metastatic and non-metastatic STSs is likely to identify genes important in the development of metastatic disease and improve our ability to prognosticate for individual patients.

Introduction

Soft tissue sarcomas (STS) are common but varied skin and subcutaneous tumors in dogs, comprised of many different tissues of origin. These tumors are locally invasive, and recurrence is common following surgical excision. The metastatic potential of individual STSs is difficult to predict, but currently is based primarily on histologic grade. Two grading schemes have been proposed to predict metastasis. The grading scheme proposed by Bostock and Dye differentiated low-grade from high-grade tumors based on mitotic index only, while a later scheme proposed by Kuntz et al. defined low-, intermediate-, and high-grade tumors based on mitotic index, tumor necrosis, and degree of differentiation (Bostock and Dye 1980; Kuntz et al.1997).

The overall metastatic rate of canine STSs has been described as 13% for low-grade tumors, 7% for intermediate-grade tumors, and 41% for high-grade tumors (Kuntz et al. 1997). However, a study by Heller et al. in 2005 identified a metastatic rate of 29.5% for low-grade

Corresponding author: Marlene Hauck, marlene_hauck@ncsu.edu, Phone: 919-513-8274, Fax: 919-513-6336.

Presented in part at the 29th Annual Conference of the Veterinary Cancer Society, Austin, Texas, October 17, 2009 and the 28th Annual Conference of the Veterinary Cancer Society, Seattle, Washington, October 19, 2008.

tumors and 34.6% for high-grade tumors, demonstrating the difficulty in applying grading schemes to predict metastasis in STS (Heller et al. 2005). Therefore, additional methods have been evaluated for predicting tumor behavior. These have included cellular proliferation markers, such as argyrophilic nucleolar organizing regions (AgNORs), Ki-67, and proliferating cell nuclear antigen (PCNA) scores, as well as evaluation of tumor microvessel density (Ettinger et al. 2006; Luong et al. 2006). Increased AgNOR and possibly Ki-67 expression was associated with decreased survival, while PCNA expression had no association with survival (Ettinger et al. 2006). Increased intratumoral microvessel density was associated with increasing grade, mitotic index, and metastatic potential (Luong et al. 2006).

The decision to administer adjuvant chemotherapy to a canine STS patient can be difficult, since less than 50% of sarcomas will metastasize despite tumor grade. The most commonly administered adjuvant chemotherapy for STS is doxorubicin (Ogilvie et al. 1989; Tilmant et al. 1986). In the only published report on the efficacy of doxorubicin in a small number of dogs with high grade STS, no benefit was found in preventing the development of metastatic disease (Selting et al. 2005). Doxorubicin has also been associated with significant side effects; in addition to bone marrow suppression and gastrointestinal toxicity, cumulative cardiotoxicity has been reported in 12–22% of dogs (Mauldin et al. 1992; Gillings et al. 2009; Page et al. 1992).

Recent studies in human medicine have analyzed gene expression signatures in various tumor types, including STSs (Baird et al. 2005; Landemaine et al. 2008; Nilbert et al. 2004; Ramaswamy et al. 2003). Unique gene expression patterns have been used to delineate specific tumor types, or to predict tumor metastasis. The objective of this study was to determine if gene expression analysis using a cDNA microarray and qRT-PCR is a feasible approach for differentiating metastatic and non-metastatic STSs in dogs, given the inherent heterogeneity in these tumors. We hypothesized that there is a unique gene expression pattern that can predict a STS's likelihood of metastasis. The ultimate goal is to identify a gene signature that is unique for metastatic sarcomas, and to use this information to screen patient tumor samples and more accurately determine the need for adjuvant chemotherapy.

Materials and Methods

Tumor samples

Samples from thirteen primary canine STS tumors (5 metastatic, 8 non-metastatic) were stabilized at room temperature in RNAlater® (Ambion, Inc., Austin, TX) and then stored at –80°C. Samples in the non-metastatic group were from patients free of metastatic disease at least one year from the time of diagnosis.

RNA extraction

Approximately 30 mg of tumor tissue was used for RNA extraction, which was performed using the Qiagen RNeasy MiniKit (Qiagen, Inc., Germantown, MD). Samples were lysed and homogenized using Qbiogene ceramic spheres (Qbiogene/MP Biomedicals, Irvine, CA) and a bead beater (BioSpec Products, Bartlesville, OK). RNA quantity and integrity was assessed with the NanoDrop (Thermo Scientific, Wilmington, DE), as well as the Agilent Technologies RNA NanoChip on the Agilent 2100 Bioanalyzer (Agilent Technologies, Inc, Santa Clara, CA). Only RNA samples with an RNA Integrity Number (RIN) of seven or greater were used for labeling and hybridization to the microarray.

Labeling and Hybridization

The Affymetrix One-Cycle Target Labeling Kit (Affymetrix, Inc., Santa Clara, CA) was used to convert RNA to cDNA and then to labeled cRNA. cRNA integrity was reassessed using the RNA NanoChip on the Agilent 2100 Bioanalyzer, and again, only cRNA with a RIN greater than or equal to seven was used. Sample cRNA was hybridized to the Affymetrix Canine Genechip® 2.0 Array (Affymetrix, Inc., Santa Clara, CA) at the Duke University Microarray Facility in Durham, NC.

Microarray Data Analysis

Microarray fluorescence was normalized using dChip software (Li and Wong 2001). Data analysis was performed using JMP/Genomics software (SAS Institute, Cary, NC) to identify genes differentially expressed between metastatic and non-metastatic tumors at a false discovery rate of 5% using ANOVA.

Primer design and efficiency calculation

Primers were designed for genes of interest based on the Affymetrix gene identifications. The specificity of each primer was verified by checking primer sequences against the National Center for Biotechnology Information (NCBI) Canine Genome with Primer-BLAST (Basic Local Alignment Search Tool) to identify possible false products. Primers were designed using Primer3 (Rozen and Skaletsky 2000) with a product size range of 80–150 base pairs. The Operon Oligo Analysis and Plotting Tool (Eurofins MWG Operon, Huntsville, AL) was used to check for primer dimers. Primers were ordered from Invitrogen (Invitrogen Corporation, Carlsbad, CA). Primer efficiencies were calculated using a standard curve containing five 1:3 serial dilutions of template. A minimum efficiency of 1.9 was required for primers to be used in this study.

Quantitative RT-PCR

RNA extracted from tumor samples (five metastatic, five non-metastatic) was converted to cDNA using the Qiagen QuantiTect Reverse Transcription Kit (Qiagen, Inc., Germantown, MD). Quantitative RT-PCR was performed using the Applied Biosystems StepOne (Applied Biosystems, Carlsbad, CA), with SYBR Green (Applied Biosystems, Carlsbad, CA) used as the fluorescent dye. The PCR cycle was followed with conditions as per manufacturer's instructions (initial activation step of 10 minutes at 95°C, then 40 cycles of 95°C for 15 seconds and 60°C for 1 minute), followed by a melt curve analysis to verify the number of products amplified. Total reaction volume was 20 µLs (1 µL (50 ng) cDNA, 10 µL SYBR green, 4 µL 1µM primer stock, and 5 µL water). Beta actin was used as the endogenous control.

Quantitative RT-PCR Data Analysis

The Pfaffl method was used to determine the relative expression levels of the genes of interest. This method takes into account the variable efficiencies of the primer sets in qRT-PCR (Pfaffl 2001). Using this method, the expression ratio for each gene was calculated by comparing expression in metastatic tumors to expression in non-metastatic tumors.

Results

Tumor samples were obtained from five dogs with metastatic and eight dogs with non-metastatic STSs. Tumor type, grade, and mitotic index are shown for each sample in Table 1. Results from the pooled microarray analysis are depicted in a cluster dendrogram (Figure 1), which is generated by JMP/Genomics software. Over 200 genes that were differentially expressed between the metastatic and non-metastatic groups were identified at a false

discovery rate of 5%. The microarray data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus (Edgar et al. 2002) and are accessible through GEO Series accession number GSE24601 (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE24601>).

For validation of the microarray results, we chose five genes of interest that were more highly expressed in metastatic STSs than in the non-metastatic group. All of these genes had at least two-fold greater expression in the metastatic group. Genes of interest were chosen based on known roles in cell division, transcription, or involvement in human cancers. These include Sprouty 2, which prevents the degradation of epidermal growth factor receptor (EGFR) and has increased expression in malignant human fibroblasts; Septin 6, which belongs to a family of GTP-binding proteins that are important in cytokinesis and has been implicated in human lymphoid neoplasia; G-protein signaling modulator 2 (GSPM2), which is involved in cell division via interaction with the nuclear mitotic apparatus protein; kinesin family member 23 (KIF 23), a microtubule-dependent “motor” involved in the transport of organelles and chromosomes in cell division that has also been shown to interact with the inhibitor of apoptosis protein BIRC6 (BRUCE); and SMAD homolog 9 (Mothers Against Decapentaplegic homolog 9), a member of the TGF- β superfamily of proteins and a regulator of transcription (Wong et al. 2001; Wong et al. 2002; Surka et al. 2002; NCBI SEPT 6 2009; NCBI GSPM2 2009; Du et al. 2001; Nislow et al. 1992; Pohl and Jentsch 2008; Du and Yip 2010; Seuntjens et al. 2009). Primers were designed for these genes of interest, and primer sequence specificity was verified with Primer-BLAST to identify possible false products. All sequences were unique to the genes of interest with the exception of the Sprouty 2 primer, which also matched a glycine product of similar size.

Validation with qRT-PCR was performed using the five metastatic tumor samples and five of the non-metastatic tumor samples (samples 6, 8, 10, 11, 13). Duplicate PCR reactions were performed for each gene of interest. Duplicate reactions with a difference in CT value >1 were excluded from analysis. Primer efficiencies used in the Pfaffl calculations are shown in Table 2. Analysis with the Pfaffl method revealed increased relative expression of all five genes of interest in the metastatic STS group (Figure 2). Sprouty 2 showed the greatest relative expression with a 96-fold higher expression in metastatic than in non-metastatic tumors. SMAD homolog 4 was used as an internal negative control, as it was not identified as a differentially-expressed gene by the microarray. This gene did not show differential expression in the qRT-PCR analysis.

Discussion

Given that the term “soft tissue sarcoma” includes a number of similarly behaving mesenchymal tumor types, it was unclear whether differences between tumor types would mask differences in gene expression between metastatic tumors and non-metastatic tumors. Therefore, the five metastatic tumor samples and eight non-metastatic tumor samples were initially selected for microarray analysis to determine the feasibility of this technique in this setting. Real-time PCR results confirmed the results of the cDNA microarray. All five genes that were identified by the microarray to have greater expression in metastatic tumors were confirmed to have increased relative expression in the metastatic tumor group by qRT-PCR. Microarrays give a broad overview of tumor gene expression at the time of biopsy and are known to contain false positives, so it is helpful to confirm results with an independent method such as qRT-PCR. Quantitative RT-PCR results were analyzed using the Pfaffl method, which accounts for the varying efficiencies of the primer sets. This is important when evaluating genes that are expressed at relatively lower frequencies in a particular sample.

Five metastatic and five non-metastatic canine STS tumor samples were used for qRT-PCR analysis. Three of the non-metastatic tumors were not used due to limited availability of RNA. Our consistent results demonstrate that the cDNA microarray and qRT-PCR are feasible methods for evaluating gene expression in STSs, as has been demonstrated in various human studies (Baird et al. 2005; Landemaine et al. 2008; Nilbert et al. 2004; Ramaswamy et al. 2003).

Specificity of all of the primer sequences were verified against the canine genome using Primer-BLAST. The Sprouty 2 primer sequence also matched a glycine product of similar size. Therefore while Sprouty 2 had considerably increased expression relative to the other genes of interest, its expression may have been artificially elevated due to the formation of a second product. In addition, the primer efficiency of Sprouty2 was calculated as greater than 100% (2.1838), which should not be possible. Determination of relative expression using the Livak method (Schmittgen and Livak 2008), which assumes 100% primer efficiencies, reveals a relative expression of 48.5, which is more consistent with the expression levels of the other genes of interest.

Eight PCR reactions were excluded from Pfaffl analysis because the difference in duplicate CT values was greater than 1. These consisted of three Sprouty 2 and GPSM2 reactions, as well as one KIF 23 and one SMAD 9 reaction. Possible explanations for the discrepancies in CT values could include pipetting errors, the formation of a second product, such as in the case of Sprouty 2, or a contaminant in any of these reactions.

Initially the primer for the SMAD gene was designed for the incorrect isoform (SMAD4 instead of SMAD9). SMAD 4 was not identified as a differentially expressed gene on the microarray, and no difference in relative expression was found using RT-PCR. This further demonstrates the agreement between the microarray and RT-PCR results.

Our results demonstrate the feasibility of using the cDNA microarray and qRT-PCR to analyze gene expression in canine STSs, with the goal of eventually using these methods for evaluating patient tumor samples and predicting tumor metastasis. The presence of intertumor heterogeneity did not prevent identification of genes associated with the metastatic phenotype. In a clinical setting, qRT-PCR is the more cost-effective method for evaluating patient samples, and therefore consistency of these results is critical. Evaluation of additional tumor samples is necessary to demonstrate the reproducibility of these results, as well as to identify a unique gene signature that is predictive of metastasis. Future studies will also include pathway analysis to better delineate the roles of genes of interest in metastasis.

Acknowledgments

The authors would like to thank Dr. Amy Pruitt, Beth Case, Dr. Kara Hoffert Goeres, and Grady Spoonamore for their assistance in collection of the hyperthermia patient samples. This work was partially supported by NIH/NCI grant no. 2PO1-CA42745 and Morris Animal Foundation grant D09CA-031.

References

- Baird K, Davis S, Antonescu CR, et al. Gene expression profiling of human sarcomas: Insights into sarcoma biology. *Cancer Res.* 2005; 65(20):9226–9235. [PubMed: 16230383]
- Bostock DE, Dye MT. Prognosis after surgical excision of canine fibrous connective tissue sarcomas. *Vet Pathol.* 1980; 17(5):581–588. [PubMed: 7404969]
- Du Q, Stukenberg PT, Macara IG. A mammalian partner of inscuteable binds NuMA and regulates mitotic spindle organization. *Nat Cell Biol.* 2001; 3(12):1069–1075. [PubMed: 11781568]

- Du Y, Yip H. Effects of bone morphogenetic protein 2 on Id expression and neuroblastoma cell differentiation. *Differentiation*. 2010; 79(2):84–92. [PubMed: 19889495]
- Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. *Nucleic Acids Res*. 2002; 30(1):207–10. [PubMed: 11752295]
- Ettinger SN, Scase TJ, Oberthaler KT, et al. Association of argyrophilic nucleolar organizing regions, Ki-67, and proliferating cell nuclear antigen scores with histologic grade and survival in dogs with soft tissue sarcomas: 60 cases (1996–2002). *J Am Vet Med Assoc*. 2006; 228(7):1053–62. [PubMed: 16579784]
- Gillings SL, Johnson J, Fulmer A, et al. Effect of a 1-hour IV infusion of doxorubicin on the development of cardiotoxicity in dogs as evaluated by electrocardiography and echocardiography. *Vet Therapeutics*. 2009; 10(1–2):46–58.
- Heller DA, Stebbins ME, Reynolds TL, et al. A retrospective study of 87 cases of canine soft tissue sarcomas, 1986–2001. *Intern J Appl Res Vet Med*. 2005; 3(2):81–87.
- Kuntz CA, Dernell WS, Powers BE, et al. Prognostic factors for surgical treatment of soft-tissue sarcomas in dogs: 75 cases (1986–1996). *J Am Vet Med Assoc*. 1997; 211:1147–1151. [PubMed: 9364229]
- Landemaine T, Jackson A, Bellahcène A, et al. A six-gene signature predicting breast cancer lung metastasis. *Cancer Res*. 2008; 68(15):6092–6099. [PubMed: 18676831]
- Li C, Wong WH. Model-based analysis of oligonucleotide arrays: Expression index computation and outlier detection. *Proc Natl Acad Sci*. 2001; 98(1):31–36. [PubMed: 11134512]
- Luong RH, Baer KE, Craft DM, et al. Prognostic significance of intratumoral microvessel density in canine soft-tissue sarcomas. *Vet Pathol*. 2006; 43(5):622–31. [PubMed: 16966439]
- Mauldin GE, Fox PR, Patnaik AK, et al. Doxorubicin-induced cardiotoxicosis: Clinical features in 32 dogs. *J Vet Intern Med*. 1992; 6:82–8. [PubMed: 1588546]
- National Center for Biotechnology Information Entrez Gene database Web site. [Accessed Nov 7, 2009.] GPSM2 G- protein signaling modulator 2 (AGS3-like, *C. elegans*) [*Homo sapiens*]. Available at: <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=29899>
- National Center for Biotechnology Information Entrez Gene database Web site. [Accessed Nov 7, 2009] SEPT6 septin 6 [*Homo sapiens*]. Available at: <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=23157>
- Nilbert M, Meza-Zepeda LA, Francis P, et al. Lessons from genetic profiling in soft tissue sarcomas. *Acta Orthop Scand*. 2004; 75(311):35–50.
- Nislow C, Lombillo VA, Kuriyama R, et al. A plus-end-directed motor enzyme that moves antiparallel microtubules in vitro localizes to the interzone of mitotic spindles. *Nature*. 1992; 359(6395):543–547. [PubMed: 1406973]
- Ogilvie GK, Reynolds HA, Richardson RC, et al. Phase II evaluation of doxorubicin for treatment of various canine neoplasms. *J Am Vet Med Assoc*. 1989; 195:1580–1583. [PubMed: 2599941]
- Page RL, Macy DW, Ogilvie GK, et al. Phase III evaluation of doxorubicin and whole-body hyperthermia in dogs with lymphoma. *Int J Hyperthermia*. 1992; 8(2):187–197. [PubMed: 1573308]
- Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. *Nucleic Acids Res*. 2001; 29:e45. [PubMed: 11328886]
- Pohl C, Jentsch S. Final stages of cytokinesis and midbody ring formation are controlled by BRUCE. *Cell*. 2008; 132(5):832–845. [PubMed: 18329369]
- Ramaswamy S, Ross KN, Lander ES, et al. A molecular signature of metastasis in primary solid tumors. *Nature Genetics*. 2003; 33:49–54. [PubMed: 12469122]
- Rozen, S.; Skaletsky, HJ. Primer3 on the WWW for general users and for biologist programmers. In: Krawetz, S.; Misener, S., editors. *Bioinformatics Methods and Protocols: Methods in Molecular Biology*. Humana Press; Totowa, New Jersey: 2000. p. 365–386.
- Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. *Nat Protoc*. 2008; 3(6):1101–8. [PubMed: 18546601]

- Selting KA, Powers BE, Thompson LJ, et al. Outcome of dogs with high-grade soft tissue sarcomas treated with and without adjuvant doxorubicin chemotherapy: 39 cases (1996–2004). *J Am Vet Med Assoc.* 2005; 227:1442–8. [PubMed: 16279389]
- Seuntjens E, Umans L, Zwijsen A, et al. Transforming Growth Factor type beta and Smad family signaling in stem cell function. *Cytokine Growth Factor Rev.* 2009; 20(5–6):449–458. [PubMed: 19892581]
- Surka MC, Tsang CW, Trimble WS. The mammalian septin MSF localizes with microtubules and is required for completion of cytokinesis. *Mol Biol Cell.* 2002; 13(10):3532–3545. [PubMed: 12388755]
- Tilmant LL, Gorman WT, Ackerman N, et al. Chemotherapy of synovial cell sarcoma in a dog. *J Am Vet Med Assoc.* 1986; 188:530–532. [PubMed: 3007411]
- Wong ES, Fong CW, Lim J, et al. Sprouty2 attenuates epidermal growth factor receptor ubiquitylation and endocytosis, and consequently enhances Ras/ERK signaling. *EMBO J.* 2002; 21(18):4796–47808. [PubMed: 12234920]
- Wong ES, Lim J, Low BC, et al. Evidence for direct interaction between Sprouty and Cbl. *J Biol Chem.* 2001; 276(8):5866–5875. [PubMed: 11053437]

Figure 1. Cluster dendrogram depicting results of the microarray analysis, generated by JMP/ Genomics software

The cluster dendrogram was derived from the pooled microarray results of the metastatic and non-metastatic tumor groups. Over 200 differentially expressed genes between the metastatic and non-metastatic groups were identified at a false discovery rate of 5%. **M** represents the metastatic and **NM** represents the non-metastatic tumor groups. Each horizontal line and corresponding code represents a single gene, with color representing genes that are linked by common structure and/or function. The logarithmic scale to the right indicates relative gene expression, with red indicating greater gene expression and blue indicating genes that are less highly expressed.

Figure 2. Expression ratio of genes of interest in the metastatic tumor group relative to the non-metastatic tumor group

Expression ratio was calculated using the Pfaffl method.

Table 1
Tumor type, grade, and mitotic index for each of the thirteen canine soft tissue sarcoma samples used in the microarray analysis

Mitotic index is defined as the number of mitotic figures per 10 high-power microscope fields. Non-metastatic tumor samples were from patients free of metastatic disease at least one year from the time of diagnosis.

Sample	Tumor Type	Tumor Grade	Mitotic Index	Metastatic or Non-metastatic
1	Fibrosarcoma	High	30	Metastatic
2	Fibrosarcoma	High	47	Metastatic
3	Fibrosarcoma	High	15	Metastatic
4	Fibrosarcoma	Low	2–5	Metastatic
5	Spindle cell sarcoma	High	42	Metastatic
6	Spindle cell sarcoma	Low	2	Non-metastatic
7	Fibrosarcoma	Low	0	Non-metastatic
8	Hemangiopericytoma	Low	3	Non-metastatic
9	Hemangiopericytoma	Low	2	Non-metastatic
10	Hemangiopericytoma	Low	1	Non-metastatic
11	Hemangiopericytoma	Low	1	Non-metastatic
12	Hemangiopericytoma	Low	6	Non-metastatic
13	Hemangiopericytoma	Low	4	Non-metastatic

Table 2**Primer efficiencies**

Efficiencies were determined for the primers for each of the genes of interest, as well as Beta actin, the endogenous control in the qRT-PCR reactions.

Primer (gene of interest)	Efficiency
Sprouty 2	2.1838
Septin 6	1.9206
GPSM2	1.915
KIF23	1.9771
SMAD 9	1.9303
SMAD 4	1.9545
Beta actin	1.9571